SecSonar.com

Organon & Co. (OGN)

Organon & Co. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Organon & Co. (OGN) is a Drug Manufacturers - General company based in US with a market capitalization of $3.5B. Revenue declined 2.9% year-over-year and the company generated $538M in free cash flow. This page tracks OGN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 10K employees · IPO May 14, 2021

Valuation

Valuation & price

$13.40 · as of May 17, 2026 · -1.1% vs 52w high

18.7

P/E ratio

Latest-FY diluted EPS

4.67

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$13.52$9.68$5.84Jul 25Dec 25Jun 26Jul 7, 25$9.72Jul 9, 25$9.91Jul 11, 25$9.94Jul 15, 25$9.56Jul 17, 25$9.64Jul 21, 25$9.45Jul 23, 25$10.10Jul 25, 25$10.21Jul 29, 25$10.14Jul 31, 25$9.70Aug 4, 25$9.67Aug 6, 25$8.72Aug 8, 25$9.22Aug 12, 25$9.05Aug 14, 25$9.39Aug 19, 25$9.26Aug 21, 25$9.28Aug 25, 25$9.06Aug 27, 25$9.20Aug 29, 25$9.42Sep 3, 25$9.83Sep 5, 25$10.38Sep 9, 25$10.37Sep 11, 25$10.66Sep 15, 25$10.40Sep 17, 25$10.45Sep 19, 25$10.45Sep 23, 25$10.54Sep 25, 25$10.12Sep 29, 25$10.35Oct 2, 25$10.94Oct 6, 25$10.84Oct 8, 25$10.24Oct 10, 25$9.60Oct 14, 25$9.56Oct 16, 25$9.38Oct 20, 25$9.24Oct 22, 25$8.94Oct 24, 25$9.16Oct 28, 25$6.66Oct 30, 25$6.57Nov 3, 25$6.71Nov 5, 25$6.38Nov 7, 25$6.78Nov 11, 25$7.52Nov 14, 25$7.53Nov 18, 25$7.71Nov 20, 25$7.13Nov 24, 25$7.06Nov 26, 25$7.74Dec 1, 25$7.60Dec 3, 25$7.27Dec 5, 25$7.14Dec 9, 25$6.95Dec 11, 25$7.36Dec 15, 25$7.02Dec 17, 25$6.99Dec 19, 25$6.83Dec 23, 25$7.09Dec 26, 25$7.18Dec 31, 25$7.17Jan 5, 26$7.44Jan 7, 26$8.19Jan 9, 26$8.05Jan 13, 26$8.43Jan 15, 26$8.70Jan 20, 26$9.46Jan 22, 26$9.74Jan 26, 26$9.10Jan 28, 26$8.89Jan 30, 26$8.54Feb 3, 26$8.00Feb 5, 26$8.10Feb 9, 26$7.91Feb 11, 26$7.69Feb 17, 26$7.28Feb 19, 26$7.52Feb 23, 26$7.92Feb 25, 26$7.51Feb 27, 26$7.29Mar 3, 26$6.90Mar 5, 26$6.71Mar 9, 26$6.53Mar 11, 26$6.40Mar 13, 26$6.35Mar 17, 26$6.39Mar 19, 26$6.27Mar 23, 26$6.09Mar 25, 26$6.10Mar 27, 26$5.84Apr 1, 26$6.14Apr 6, 26$6.05Apr 8, 26$5.86Apr 10, 26$8.83Apr 14, 26$8.70Apr 16, 26$9.33Apr 20, 26$9.26Apr 22, 26$9.14Apr 24, 26$11.26Apr 28, 26$13.32Apr 30, 26$13.25May 4, 26$13.26May 6, 26$13.41May 8, 26$13.35May 12, 26$13.31May 15, 26$13.40May 19, 26$13.42May 21, 26$13.42May 26, 26$13.41May 28, 26$13.35Jun 1, 26$13.36Jun 3, 26$13.40Jun 5, 26$13.36Jun 9, 26$13.40Jun 11, 26$13.45Jun 15, 26$13.44Jun 17, 26$13.42Jun 22, 26$13.40Jun 24, 26$13.48Jun 30, 26$13.52
$5.7052-week range$13.55
Loading valuation history…

Fundamentals

Key fundamentals

$3.5B

Market cap

-2.9%

Revenue growth (YoY)

54.1%

Gross margin

$538M

Free cash flow (USD)

$8.2B

Net debt

0.9%

Share dilution

3/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2017 → 2025

FY 2017$10.5BFY 2018$9.8BFY 2019$7.8BFY 2020$6.5BFY 2021$6.3BFY 2022$6.2BFY 2023$6.3BFY 2024$6.4BFY 2025$6.2B
$10.5B$6.2B

Free cash flow by year

2017 → 2025

FY 2017$3.3BFY 2018$3.6BFY 2019$2.7BFY 2020$1.9BFY 2021$2.0BFY 2022$431.0MFY 2023$538.0MFY 2024$588.0MFY 2025$538.0M
$3.3B$538M

Gross margin by year

2021 → 2025

FY 202162.2%FY 202262.8%FY 202359.8%FY 202458.0%FY 202554.1%
62.2%54.1%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

1

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 4, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventIncentive Stock Plan AmendedJun 11, 2026Filing
  • Insider buyInsider Buy $353KHolzbaur Lynette · SVP and Corporate Controller · $353.1KMay 7, 2026Filing
  • Insider sellInsider Sell $353KHolzbaur Lynette · SVP and Corporate Controller · $353.1KMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 4, 2026Filing
  • 8-K eventEarnings ReleaseApr 30, 2026Filing
  • 8-K eventMerger AgreementApr 27, 2026Filing

Questions

Frequently asked questions

What is Organon & Co.'s market cap?

Organon & Co. (OGN) has a market capitalization of $3.5B.

What is OGN's P/E ratio?

OGN trades at a price-to-earnings ratio of 18.7, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is OGN's price-to-book (P/B) ratio?

OGN trades at 4.67 times book value per share.

Are insiders buying OGN stock?

Yes — SEC Form 4 filings show 1 open-market insider buy and 1 sell at Organon & Co. in the last 90 days.

Same arena

Related companies in Drug Manufacturers - General

GRFS

Grifols, S.A.

$6.7B

SCLX

Scilex Holding Company

$79M

SRXH

SRx Health Solutions Inc.

$3.9M

BIIB

Biogen Inc.

$29.2B

ZTS

Zoetis Inc.

$32.6B

GSK

GSK plc

$101.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.